Press release
Immunotherapy, The Most Prominent Topic In Skin Cancer Research
A report published on May, 21, 2019 highlights the different research areas in the field of skin cancer, showing that immunotherapy is the most prominent topic and reveals the countries that are driving this research. The study, “Melanoma Research Insights: Impact, Trends, Opportunities”, released during Skin Cancer Awareness Month by information analytics business Elsevier, maps and analyses academic research on melanoma globally between 2013-2018.Findings in the report highlight that melanoma research accounted for 4-5 percent of all cancer research output globally over the past two decades, with just under 50,000 melanoma research papers published between 2013 and 2018, suggesting more research can be done.
Immunotherapy, treatment of cancer with substances that strengthen the body’s natural immune response, is the most prominent topic within melanoma research, accounting for 4.9 percent of papers published between 2013 and 2018.
Specifically, research has centred around newly developed immunotherapies, such as nivolumab, ipilimumab and lambrolizumab. The top 10 immunotherapy papers include research on both monotherapies, or single-drug therapies, and drug combinations. While most melanoma research is taking place in medicine, the field of computer science is also making an impact, particularly in melanoma diagnostics.
Research output is dominated by researchers based in the United States, with close to 18,000 papers published within the time period. However, surprisingly, Italy’s relative level of focus on melanoma was greater than the United States’ as the scale of Italy’s research into melanoma as a proportion of its total research portfolio is above the global average.
Further findings highlighted in the report
Of the top 10 countries by research output in melanoma research:
Five were European (Germany, Italy, UK, France and Spain), collectively accounting for 15,688 papers published.
When research is compared to the rate of melanoma at a country level, only Australia and Germany from the top 10 countries in terms of melanoma rates are also in the top 10 most active countries engaging in melanoma research.
Northern and Central European countries are among some of the most common places where melanoma is diagnosed, however, they did not appear in the top 10 list of countries engaged in the research of the cancer.
Top 10 countries by scholarly output in melanoma research (2013-2018)
1.United States
2.China
3.Germany
4.Italy
5.United Kingdom
6.France
7.Australia
8.Japan
9.Spain
10.Canada
As part of the report, Elsevier also conducted a literature review into melanoma research and highlighted some findings related to skin color and melanoma.
Despite being more at risk of dying from melanoma, there is a gap in the knowledge on strategies to prevent and detect melanoma in darker skinned people.
The small amount of research conducted into the experience of dark-skinned people who develop melanoma, has also revealed ethnic and racial gaps in the research literature. These gaps include an unclear definition of ethnic minorities; false assumptions among dermatologists that ethnic minorities are less at risk for UV-induced skin cancer; and false beliefs among ethnic minorities that dark pigmentation protects against skin cancer.
Although dark-skinned people are less likely than light-skinned individuals to develop melanoma, those who do develop the disease face a significantly higher risk of mortality, with five-year survival ranging from 72 percent for African Americans to 81 percent for Hispanics – compared to close to 90 percent for Caucasians (based on US studies).
As this report shows, melanoma is a significant focus of academic research globally, and while it is clear that patients are benefiting from the latest research into novel therapies to treat melanoma, there are gaps that need to be addressed with more research.
Biochempeg, a professional PEG derivatives supplier supplies PEG linkers, monodisperse PEG, Click Chemistry reagents, PEGylation services and custom PEG derivative synthesis to clients worldwide. It offers a selection of PEG derivatives for cancer research including melanoma research, breast cancer research, diabetes research and so on.
About us
Company: Biochempeg Scientific Inc.
Address: 108 Water Street, Room 4D, Watertown, MA 02472, USA
Email: sales@biochempeg.com
Website: https://www.biochempeg.com
Biochempeg is a biotechnology-oriented company in Watertown, Massachusetts. We are dedicated to manufacturing and supplying high purity polyethylene glycol (PEG) derivatives and reagents, monodisperse PEG, Click Chemistry reagents, PEGylation services and custom PEG derivative synthesis to clients worldwide. These PEG reagents have been widely used in bioconjugation, antibody-drug conjugates (ADCs) therapeutic, drug delivery and diagnostics field.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immunotherapy, The Most Prominent Topic In Skin Cancer Research here
News-ID: 2192671 • Views: …
More Releases from Biochempeg Scientific Inc.

Biopharma PEG Provides Multi-arm PEG Derivatives Crosslinked Into Hydrogels
Polyethylene (ethylene glycol) is a hydrophilic polymer that can have a very high water content when cross-linked into a network. Polyethylene glycol (PEG) is a suitable material for biological applications because it does not normally elicit an immune response. Since the 1970s, PEG has been used to modify therapeutic proteins and peptides in order to increase their solubility, reduce their toxicity, and prolong their cyclic half-lives. In the late 1970s,…

Semaglutide VS Liraglutide: Which Is Better For Weight Loss
Among adults with overweight or obesity, once-weekly subcutaneous semaglutide plus counseling for diet and physical activity results in significantly greater weight loss at 68 weeks than once-daily subcutaneous liraglutide, according to a study published in the Jan. 11 issue of the Journal of the American Medical Association.
Domenica M. Rubino, M.D., from the Washington Center for Weight Management and Research in Arlington, Virginia, and colleagues compared the efficacy and adverse event…

What Are Components And Mechanism Action of Antibody-Drug Conjugates
Antibody-Drug Conjugates (ADC) is a type of anticancer drug that links a drug to cancer-targeting antibodies. The antibody detects tumor-specific proteins expressed on cancer cells and directs the cytotoxic anticancer drug towards the cancer cell.
Compared to alternative cancer treatments, for example, chemotherapy, immunotherapy, radiation, and stem cell therapy, ADC combines chemotherapy and immunotherapy and allows selective delivery of anticancer drugs and reduces systemic exposure and toxicity of anticancer drugs.
Components of ADC
One…

Sacituzumab govitecan shows promise in treating the most aggressive type of brea …
A unique antibody drug conjugate (ADC), which delivers a high dose of a cancer-killing drug to tumor cells through a targeted antibody, has been found in a global phase 3 clinical study to nearly double the survival time of patients with refractory metastatic triple-negative breast cancer. The study of the ADC drug sacituzumab govitecan (SG), for which Massachusetts General Hospital (MGH) was a lead clinical research site after serving as…
More Releases for PEG
Biopharma PEG Delivers Innovative PEG Solutions for Enhanced Drug Efficacy
Watertown, MA - October 24, 2024 - Biopharma PEG is excited to announce its extensive offerings of polyethylene glycol (PEG) products, including monofunctional, homobifunctional, heterobifunctional, and multi-arm PEGs, tailored for PEGylation in biopharmaceutical applications. With over 40 PEGylated drugs approved globally, the role of PEGylation in drug development is more critical than ever.
PEGylation provides numerous advantages, such as improved solubility, enhanced stability, and increased circulation time in the bloodstream. By…
Biopharma PEG Expands Multi-Arm PEG Product Line
Biopharma PEG, a leader in PEG derivatives, is excited to announce the expansion of its high-purity Multi-Arm PEG linker product line, catering to the evolving needs of the medical and bioorganic fields. These advanced PEG linkers are available in various functional groups and molecular weights ranging from 1k to 40k, offering unmatched versatility and performance for research and development in cutting-edge medical applications.
"Biopharma PEG is committed to delivering high-purity multi-arm…
Biopharma PEG Supplies PEG Products Used For Infectious Disease Vaccines
As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development.
Recombinant protein vaccines accounted for the largest proportion of all pipeline in development, 22% (215), due…
Biopharma PEG Supplies PEG Products For Click Chemistry Reactions
What is "click chemistry"? "Click Chemistry", this is a literary name given to this kind of reaction by the Nobel Prize winner K.Burry Sharless, when the cards are put together, "click" (click). Simply put, it is to add two structures to two molecules respectively, and these two structures can be specifically combined to synthesize the required chemical molecules. One of the most famous click-chemistry reactions is the Cu-catalyzed azide-alkyne cycloaddition…
Biopharma PEG Develops PEG Linkers for Antibody Drug Conjugates
Antibody-drug conjugate (ADC) is one of the fastest growing fields in tumor therapy, which consists of monoclonal antibody (Antibody), linker (Linker) and active drug (Payload). So far, there are only 15 drugs on the market in the world. However, with the development of some perfect antibody modification techniques, advanced site-specific coupling techniques and powerful small-molecule toxins, ADC drug research has mushroomed and a large number of ADC drugs are in…
Biopharma PEG Provides Multi-arm PEG Derivatives Crosslinked Into Hydrogels
Polyethylene (ethylene glycol) is a hydrophilic polymer that can have a very high water content when cross-linked into a network. Polyethylene glycol (PEG) is a suitable material for biological applications because it does not normally elicit an immune response. Since the 1970s, PEG has been used to modify therapeutic proteins and peptides in order to increase their solubility, reduce their toxicity, and prolong their cyclic half-lives. In the late 1970s,…